Results 221 to 230 of about 29,849 (247)
Some of the next articles are maybe not open access.
Efficacy of Pneumococcal Polysaccharide Vaccines
Clinical Infectious Diseases, 1981due to pneumococcal infection. Estimates based on data obtained in this country after licensure of the vaccine suggest that the efficacy in certain groups may be low:
openaire +2 more sources
Polysaccharide Meningococcal Vaccines—Current Status
Hospital Practice, 1979Two separate periods of intensive research, with a 25-year hiatus after the advent of the sulfonamides, have resulted in two good, but imperfect, antimeningococcal vaccines--against serogroups A and C. Neither is recommended for routine use, but both have been effective in halting epidemics.
openaire +2 more sources
[Polysaccharide subunit vaccines].
La Revue du praticien, 1995The polysaccharide capsules of many germs (pneumococcus, meningococcus, Haemophilus b, salmonella, etc.) can induce synthesis of protective antibodies in man. The development of many vaccines has been based on this phenomenon. Unfortunately, the polysaccharide antigens cannot trigger an immune response before the age of 2 years.
openaire +1 more source
Bacterial Polysaccharide Vaccines
2011Capsulated bacteria, Gram-positive or Gram-negative, cause a variety of infections in man. Prominent among them are streptococci of Lancefield’s groups A, B, and C, staphylococci, meningococci, Haemophilus influenzae type b, klebsiellas, Escherichia coli, and Salmonella typhi, to name but some.
openaire +1 more source
Pneumococcal polysaccharide vaccines
The Indian Journal of Pediatrics, 1982openaire +2 more sources
Chemically Modified Capsular Polysaccharides as Vaccines
1988Capsular polysaccharides have assumed an important role as vaccines against disease caused by bacteria in humans. The concept of using pure definable polysaccharides devoid of their accompanying complex bacterial mass is technically elegant and is obviously capable of extension into other areas of immunoprophylaxis.
openaire +3 more sources